Avidity Partners, an investment management firm that offers financial services, led a $50m Series D funding round in Calyxo, a medical device company developing next-generation treatment solutions for patients with kidney stones, with participation from Questa Capital and CRG. “We are excited about this round of funding which will further accelerate the company’s momentum. Despite the challenging market conditions, we received strong support from investors who believe in our team, our mission and the promise of our CVAC technology. Our kidney stone treatment innovations will improve care for patients and have the opportunity to transform the way this condition is treated. We will use this capital to build commercial traction while maintaining investment in product development and clinical studies,” Joe Catanese Calyxo President & CEO.